MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Guardant Health Inc

Fermé

SecteurSoins de santé

93.86 2.95

Résumé

Variation du prix de l'action

24h

Actuel

Min

93.14

Max

93.98

Chiffres clés

By Trading Economics

Revenu

-36M

-128M

Ventes

16M

281M

BPA

-0.5

Marge bénéficiaire

-45.684

Employés

2,490

EBITDA

-37M

-119M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+41.45% upside

Dividendes

By Dow Jones

Prochains Résultats

29 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-2.3B

11B

Ouverture précédente

90.91

Clôture précédente

93.86

Sentiment de l'Actualité

By Acuity

50%

50%

146 / 349 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Guardant Health Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 avr. 2026, 04:27 UTC

Principaux Événements d'Actualité

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3 avr. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 avr. 2026, 18:30 UTC

Principaux Événements d'Actualité

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 avr. 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 avr. 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 avr. 2026, 17:44 UTC

Acquisitions, Fusions, Rachats

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 avr. 2026, 16:50 UTC

Principaux Événements d'Actualité

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 avr. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 avr. 2026, 16:12 UTC

Résultats

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 avr. 2026, 15:56 UTC

Market Talk
Principaux Événements d'Actualité

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 avr. 2026, 15:56 UTC

Market Talk
Principaux Événements d'Actualité

Global Equities Roundup: Market Talk

3 avr. 2026, 15:56 UTC

Market Talk
Principaux Événements d'Actualité

Global Forex and Fixed Income Roundup: Market Talk

3 avr. 2026, 15:20 UTC

Principaux Événements d'Actualité

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 avr. 2026, 15:08 UTC

Acquisitions, Fusions, Rachats

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 avr. 2026, 14:11 UTC

Market Talk
Principaux Événements d'Actualité

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 avr. 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 avr. 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 avr. 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3 avr. 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 avr. 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 avr. 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 avr. 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3 avr. 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 avr. 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3 avr. 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 avr. 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3 avr. 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3 avr. 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3 avr. 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3 avr. 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Comparaison

Variation de prix

Guardant Health Inc prévision

Objectif de Prix

By TipRanks

41.45% hausse

Prévisions sur 12 Mois

Moyen 132.72 USD  41.45%

Haut 175 USD

Bas 110 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

20 ratings

19

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

38.86 / 47.41Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

146 / 349Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat